Rare Daily Staff
The Edison Awards named the n-Lorem, a nonprofit developer of rare disease therapies for populations of one to 30 patients, a 2023 Edison gold award winner in the Treatment Optimization category for Health, Medical, and Biotech.
The award recognizes n-Lorem’s innovative, non-profit approach to discover, develop, and provide individualized, experimental antisense oligonucleotide medicines for nano-rare populations of patients with the same single gene mutation worldwide for free for life.
“What we are doing at n-Lorem for nano-rare patients is truly extraordinary and unique,” said Stanley Crooke, founder, chairman and CEO of n-Lorem Foundation. “Already we have accepted more than 90 patients into our program and expect this number to continue to increase as more patients are treated and more patients find their way to n-Lorem.”
The Edison Awards honor excellence in new product and service development, marketing, human-centered design and innovation. In its 36th year, the annual competition recognizing world-changing innovations and the minds behind them. Previous winners include Moderna, Merck, and Steve Jobs. The Edison Awards are inspired by Thomas Edison, the iconic inventor with 1,093 U.S. patents.
Stay Connected
Sign up for updates straight to your inbox.